RxDoctor Payments Data

Maryam Rahmanian, NP

Family · West Hills, CANPI 1851913768

Payments from drug & device makers

$4,364in general payments, 2019–2025

Across 194 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$670
  • Johnson & Johnson$534
  • Pfizer$471
  • AstraZeneca$381
  • Boehringer Ingelheim$304
  • Lexicon Pharmaceuticals, Inc.$278
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$4,350100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,364 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$18,687
Medicare patients
118
Services billed
262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$173,153
EntrestoSacubitril/Valsartan61$73,779
FarxigaDapagliflozin Propanediol45$37,525
JardianceEmpagliflozin33$36,364
XareltoRivaroxaban13$17,882
Metoprolol Succinate181$2,513
Nifedipine ErNifedipine30$1,563
Amlodipine Besylate369$1,248
Hydralazine Hcl116$1,187
Carvedilol166$1,131
Losartan Potassium140$1,066
Atorvastatin Calcium96$871
Lisinopril139$818
Digoxin31$652
Isosorbide Mononitrate ErIsosorbide Mononitrate57$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$471$173,153153 claims
NovartisEntresto$268$73,77961 claims
AstraZenecaFarxiga$381$37,52545 claims
Boehringer IngelheimJardiance$304$36,36433 claims
Johnson & JohnsonXarelto$534$17,88213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →